Floatz logo

Kras Tcr-Transduced Pbl

Duodenum Cancer

National Cancer Institute (NCI)Cell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Duodenum Cancer cohort.

Asset / SponsorPhaseRating
N-Butyl Cyanoacrylate
Minia University
Phase 3B
Apixaban
Asan Medical Center
Phase 2CCC
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2CCC
Rivaroxaban
Asan Medical Center
Phase 2CCC
Pantoprazole
Washington University School of Medicine
Phase 2CCC
Fludarabine
National Cancer Institute (NCI)
Phase 2CCC
Dalteparin
Asan Medical Center
Phase 2CCC
Irinotecan
University of Southern California
Phase 1CC

Same molecule, other indications

Kras Tcr-Transduced Pbl is also rated in:

metastatic malignant neoplasmActive
B
Indicative · Phase 2
59 / 100
View asset →
hepatocellular carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
digestive system carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →